Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) announced the issuance of an Australian patent covering its Bisphosphocin® compounds, which are being developed to treat antimicrobial infections including complicated urinary tract infections and pulmonary infections.

The patent, titled "Antimicrobial Compounds, Compositions, and Uses Thereof," was issued March 5, 2026, by IP Australia. According to a company statement, Lakewood-Amedex's intellectual property portfolio now includes 72 granted patents and 29 pending patents across multiple countries and regions, including the United States, the European Patent Office, China, India, Japan, Mexico, Hong Kong, the Republic of Korea, Brazil, the United Kingdom, New Zealand, and Australia.

Chief Executive Officer Kelvin Cooper said, "This newly issued patent adds to our international intellectual property portfolio covering composition of matter patents for the Bisphosphocin® class of compounds."

Lakewood-Amedex describes itself as a clinical-stage biotechnology company developing antimicrobials targeting antibiotic-resistant bacterial strains, including MRSA and VRE.